Resource allocation between the optimal threshold value and budget: Methods for developing a cost-effectiveness threshold value;Ressourcenallokation im spannungsverhältnis zwischen optimalem schwellenwert und optimalem budget: Ansätze zur sichtbarmachung und herleitung eines kosteneffektivitätsschwellenwerts

Gesundheitsokonomie und Qualitatsmanagement

Volumn 11, Issue 5, 2006, Pages 302-310

  Schumann, A ^a   Schöffski, Oliver ^b  

^a BUNDESWEHR UNIVERSITY MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Budget constraints; Cost effectiveness threshold value; Resource allocation; Shadow price concept; Threshold value

Indexed keywords

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; QUALITY OF LIFE; RESOURCE ALLOCATION;

EID: 33750629024     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926697     Document Type: Article

References (54)

1. Sendi P, Briggs AH. Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane. Health Economics 2001; 10: 675-680
2. World Health Organization (WHO). Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for economic development. Genf: WHO, 2001
3. Coast J. Who wants to know if their care is rationed? Views of citizens and service informants. Health Expectations 2001; 4: 243-252
4. Eichler HG, Kong SX, Gerth WC et al. Use of Cost-Effectiveness Analysis in health-care resource allocation decision-making: How are Cost-Effectiveness thresholds expected to emerge? Value in Health 2004; 7: 518-528
5. Card WI, Mooney GH. What is the menetary value of a human life? The British Medical Journal 1977; 2: 1627-1629
6. Weinstein M, Zecfchauser R. Critical ratios and efficient allocation. Journal of Public Economics 1973; 2: 147-157
7. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. Journal of Health Economics 1993; 12: 459-467
8. Anell A. Priority setting for pharmaceuticals. European Journal of Health Economics 2004; 1: 28-35
9. Karlsson G, Johannesson M. The decision rules of Cost-Effectiveness Analysis. PharmacoEconomics 1996; 9: 113-120
10. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1982; 1: 61-80
11. Laupacis A, Feeny D, Detsky AS et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 1992; 146: 4, 473-481
12. Naylor CD, Williams JI, Basinski A et al. Technology assessment and cost-effectiveness analysis: Misguided guidelines? Canadian Medical Association Journal 1993; 148: 6, 921-924
13. Pyne JM, Rost KM, Zhang M et al. Cost-effectiveness of a primary care depression intervention. Journal of General Internal Medicine 2003; 18: 432-441
14. Chapman RH, Berger M, Weinstein MC et al. When does quality-adjusted life-years matter in cost-effectiveness analysis? Health Economics 2004; 13: 429-436
15. Owens DK. Interpretation of Cost-Effectiveness Analysis. Journal of General Internal Medicine 1998; 13: 10, 716
16. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG). Methoden. Köln: IQWIG, 2005
17. Horowitz NS, Gibb RK, Menegakis NE et al. Utility and Cost-Effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstetrics and Gynecology 2002; 99: 5, 771-776
18. Martin SC, Gagnon DD, Zhang Z et al. Cost-Utility Analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. PharmacoEconomics 2003; 21: 16, 1153-1169
19. McIntosh EDG, Conway P, Willingham J et al. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococal conjugate vaccine. Vaccine 2003; 21: 2564-2572
20. Garber AM, Phelps CE. Economic foundations of Cost-Effectiveness Analysis. Cambridge, 1992
21. World Health Organization (WHO). The World Health Report 2002. Genf: WHO, 2002
22. Laupacis A, Feeny D, Detsky AS et al. Tentative guidelines for using clinical nd economic evaluations revisited. Canadian Medical Association Journal 1993; 148: 6, 927-929
23. Weinstein MC. From cost-effectiveness ratios to resource allocation: Where to draw the line? In: Sloan FA (Hrsg). Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 77-97
24. Sendi P, Al MJ, Gafni A et al. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Social, Science and Medicine 2003; 57: 2207-2215
25. Culyer T. Introduction: Ought NICE to have a cost-effectiveness threshold? In: Towse A, Pritchard C, Devlin N (Hrsg). Cost-Effectiveness thresholds: Economic and ethical issues. London: King's Fund, 2002: 9-14
26. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. The British Medical Journal 2001; 323: 1300-1303
27. Rothgang H, Niebuhr D, Wasem J et al. Das National Institute for Clinical Excellence (NICE) - Staatsmedizinisches Rationierungsinstrument oder Vorbild für die evidenzbasierte Bewertung medizinischer Leistungen? Gesundheitswesen 2004; 66: 303-310
28. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): Is economic appraisal working? PharmacoEconomics 2002; 20: 3, 95-105
29. Towse A, Pritchard C. Does NICE have a threshold? An external view. In: Towse A, Pritchard C, Devlin N (Hrsg). Cost-Effectiveness thresholds: Economic and ethical issues. London: King's Fund, 2002: 25-30
30. National Institute for Clinical Excellence (NICE). Correction of factual inaccuracies and process misunderstandings. Stand 31. 7.2005. http://www.nice.org.uk/pdf/PaperTwo.pdf
31. Littlejohns P. Does NICE have a threshold? A response. In: Towse A, Pritchard C, Devlin N (Hrsg). Cost-Effectiveness thresholds: Economic and ethical issues. London: King's Fund, 2002: 31-37
32. National Institute for Clinical Excellence (NICE). Guidance on the use of orlistat for the treatment of obesity in adults, technology appraisal guidance No. 22. Stand 31.7.2005http://www.nice.org.uk/pdf/orlistatguidance.pdf
33. Towse A, Pritchard C, Devlin N. Cost-Effectiveness thresholds: Economic and ethical issues. London: King's Fund, 2002
34. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factores influence its decisions? A binary choice analysis. Health Economics 2004; 13: 437-452
35. Breyer F, Zweifel P, Kifmann M. Gesundheitsökonomie. Berlin: Springer, 2005
36. Johansson PO. Evaluating health risks: An economic approach. Cambridge: Cambridge University Press, 1995
37. Pauly MV. Valuing health care benefits in money terms In: Sloan FA (Hrsg). Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 99-124
38. Birch S, Gafni A. Cost effectiveness/utility analysis: Do current decision rules lead us to where we want to be? Journal of Health Economics 1992; 11: 279-296
39. Richardson J. The role of willingness-to-pay in resource allocation in a national health scheme. West Heidelberg: CHPE, 1999
40. Al MJ, Feenstra T, Brouwer WBF. Decision makers' views on health care objectives and budget constraints: results from a pilot study. Health Policy 2004; 70: 33-48
41. Greiner W, Schöffski O. Grundprinzipien einer Wirtschaftlichkeitsuntersuchung. In: Schöffski O, Schulenburg JMG vd (Hrsg). Gesundheits-ökonomische Evaluationen. Berlin: Springer: 205-229
42. Kriedel T. Effizienzanalysen von Gesundheitsprojekten: Diskussion und Anwendung auf Epilepsieambulanzen. Berlin: Springer, 1980
43. Richardson J. Returns on investment in public health: Comments on the report by applied economics. West Heidelberg: CHPE, 2004
44. Tengs TO, Adams ME, Plinskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 3, 369-390
45. Ramsberg JAK, Sjoberg L. The cost-effectivenss of lifesaving interventions in Sweden. Risk Analysis 1997; 17: 467-478
46. Loomes G. Valuing life years and QALYs: Transferability and convertibility of values across the UK public sector. In: Towse A, Pritchard C, Devlin N (Hrsg). Cost-Effectiveness thresholds: Economic and ethical issues. London: King's Fund, 2002: 46-55
47. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evalution of health care technologies. Journal of Health Economics 1999; 18: 341-364
48. Sendi P, Gafni A, Birch S. Opportunity cost and uncertainty in the economic evaluation of health care interventions. Health Economics 2002; 11: 23-31
49. Torrance GW, Siegel JE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Siegel JE., Russell LB et al (Hrsg). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 54-81
50. Doyal L. The rationing debate: Rationing within the NHS should be explicit: The case for. The British Medical Journal 1997; 314: 1114
51. Johannesson M. Theory and methods of economic evaluation of health care. Dordrecht: Kluwer Academic Publishers, 1996
52. Gafni A, Birch S. Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal 1993; 148: 6, 913-917
53. Johannesson M, Meltzer D, O'Conner RM. Incorporating future costs in medical Cost-Effectiveness Analysis: Implications for the Cost-Effectiveness of treatment of hypertension. Medical Decision Making 1997; 17: 382-389
54. Drummond MF, O'Brien B, Stoddart GL et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997